NanoBio Corporation recently celebrated the issuance of U.S. Patent No. 9,492,525 for its Human Respiratory Syncytial Virus (RSV) vaccine.
The patent covers NanoBio’s intramuscular and intranasal candidates developed as RSV vaccines. Vaccine candidates are a combination of NanoBio’s innovative nanoemulsion (NE) adjuvant and RSV strain L19.
NanoBio is currently pursuing patents that would cover NE adjuvant as well as other strains of RSV combinations.
"This critical patent strengthens NanoBio's position as we prepare to advance our NE RSV vaccine into clinical studies," NanoBio Senior Vice President of Vaccine Research and Development Dr. Ali Fattom said. "Based on our research to date, the use of whole inactivated RSV L19 in combination with our NE adjuvant elicits robust protection across multiple strains of RSV in both cotton rats and non-human primates, without evidence of safety concerns or the enhancement of disease observed with prior formalin-inactivated vaccines."
The combination of the RSV L19 virus strain and NE adjuvant not only splits the virus -- it fully inactivates it. This occurs due to inherent antimicrobial properties, which are possessed by the adjuvant.
However, the L19 native viral proteins’ immunogenicity remains preserved throughout the process. As a result, the NE RSV vaccine includes all of the viral epitopes.
